

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

KERYX BIOPHARMACEUTICALS INC

Form 8-K

May 07, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): MAY 7, 2004

KERYX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

DELAWARE	000-30929	13-4087132
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

750 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(c) Exhibits

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

The following exhibit is filed as a part of this report:

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Press Release dated May 7, 2004.

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On May 7, 2004, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a press release announcing results of operations for the first quarter ended March 31, 2004. Keryx also announced that it would host a conference call on May 10, 2004 for investors where Keryx will discuss its results of operations and financial results. A copy of such press release is attached to this current report on Form 8-K as Exhibit 99.1 and is being furnished under Item 12 of Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KERYX BIOPHARMACEUTICALS, INC.
(Registrant)

Date: May 7, 2004

By: /s/ Ron Bentsur

Ron Bentsur
Vice President Finance and
Investor Relations

INDEX TO EXHIBITS

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Press Release dated May 7, 2004.

